🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Board Director Changes SEC Filings — February 27, 2026

Across 36 SEC 8-K filings dated February 27, 2026, focused on USA Board Room Changes, the dominant theme is elevated executive and board churn with 18 resignations/retirements (mostly planned, no disagreements cited) and 12 appointments/promotions, signaling routine refreshment amid neutral sentiment in 85% of cases. Positive signals emerge from compensation expansions (e.g., Ambarella's FY2027 bonus pool 28% larger YoY, Lesaka's CEO salary to $503K) and high-profile hires (e.g., Northpointe's ex-regulator Rodney Hood, Aurora's ex-Meta CFO David Wehner), indicating retention efforts in growth sectors like fintech and tech. No broad period-over-period financial deteriorations noted, but unknown details in 11 Item 5.02 filings (e.g., Trimas, Smurfit Westrock) raise opacity risks; forward-looking comp plans target 2026 performance with upside to 200% bonuses. Financials/banks show highest volume (9 filings), suggesting sector-wide governance tuning ahead of AGMs. Portfolio implications: leadership stability generally intact, but monitor small caps (materiality 7-9/10) for execution risks; actionable alpha in comp hikes signaling management conviction.

36 high priority 36 total filings
· daily

US Merger & Acquisition SEC Filings — February 27, 2026

A surge in SPAC activity dominates the 9 filings from February 27, 2026, with 3 new SPAC IPOs raising a combined $586M ($125M Clearthink, $261M MOZAYYX upsized, $200M TRG Latin America), signaling robust investor appetite for blank-check companies targeting financial services, general M&A, and Latin America. De-SPAC progress is evident in Real Asset Acquisition Corp.'s definitive agreement with IQM Finland for quantum computing (potential Nasdaq listing) and Voyager Acquisition Corp.'s merger approval with VERAXA Biotech (Nasdaq: VRXA post-close). Avidity Biosciences reports a completed takeover with change of control, delisting, and agreement termination, marking a rare public-to-private shift. Vague filings from Abony, Roman DBDR, and Miluna highlight undisclosed M&A or governance events amid neutral sentiment. No period-over-period financial trends available across filings, but transaction volumes indicate heightened M&A momentum in tech/biotech/SPACs versus subdued traditional M&A. Capital allocation absent; forward-looking catalysts include IPO closings Feb 25-27, 2026, and conference calls. Implications: SPAC IPO boom offers entry points for merger arbitrage, while delisting/takeover in Avidity flags liquidity risks.

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — February 27, 2026

Across 94 overnight SEC 8-K filings from Feb 26-27, 2026, the dominant theme is a surge in earnings-related disclosures (approx. 40 filings with Item 2.02), signaling peak earnings season with neutral sentiment in all cases due to undisclosed quantitative metrics like YoY/QoQ revenue growth or margins. A notable cluster of 15+ material definitive agreements (Item 1.01) points to heightened M&A activity across sectors like pharma, energy, and tech, potentially indicating consolidation plays though terms remain undisclosed. No insider trading activity, capital allocation details (dividends/buybacks), or forward-looking guidance changes are disclosed in any filing, limiting precise trend synthesis; however, period-over-period comparisons are absent across the board. One critical bearish outlier: Datavault AI Inc. delisting notice (materiality 10/10). Portfolio-level patterns show pharma/biotech (12+ filings) and energy/funds (15+) leading volume, with overall low-medium risk and neutral-to-mixed sentiment implying stable but opaque pre-market positioning. Actionable implication: Monitor exhibits/press releases for hidden beats/misses in high-materiality earnings (avg materiality 6-8/10); M&A clusters offer alpha if accretive.

21 high priority 73 medium 94 total filings
· daily

Biotech Small-Cap Approvals — February 26, 2026

A cluster of 5 approvals for BRIVARACETAM (1 bullish, 4 neutral ANDAs) signals intensifying generic competition, likely eroding pricing for originators while enabling portfolio expansion for small-cap generics firms. Vanda Pharms' NME approval for milsaperidone stands out as a high-potential novel asset with exclusivity. Neutral overall due to unspecified indications across 7/8 records, limiting market sizing; no risks beyond routine generic pressures.

8 total filings
· daily

New Drug Approvals (Original) — February 26, 2026

A cluster of five Brivaracetam approvals (one bullish original for Hainan Poly, four neutral ANDAs) signals imminent generic erosion in the US market, pressuring originator revenues while enabling volume-driven growth for generic sponsors. Bullish catalysts include Vanda Pharms' NME approval for milsaperidone and Hainan Poly's Brivaracetam nod, marking rare novel entries amid seven standard-review approvals. Neutral impacts dominate from unspecified indications across all records, limiting precise market sizing but highlighting generic portfolio expansions for Asian and specialty firms.

8 total filings
· daily

Federal Professional Services Contracts — February 26, 2026

Ameresco Inc. won a $217M firm fixed-price GSA delivery order for 19-year deep energy retrofits at 25 federal buildings in Region 5, signaling strong federal commitment to energy savings programs. This provides long-term revenue stability with $11.8M in options, but execution risks loom due to the extended timeline and no initial outlays. Investors should view this as a bullish catalyst for energy services firms targeting government contracts.

1 total filings
· daily

All NASA Contracts — February 26, 2026

A single $138.8M NASA contract to ALCYON TECHNICAL SERVICES (ATS) JV, LLC for facilities support and logistics at Glenn Research Center shows steady execution with $66M outlayed over 10+ years but signals neutral investment outlook due to high subcontractor reliance (56% of value) and nearing end in March 2026. Risks center on execution variability in cost-plus structure and dependency on 952 subawards totaling $77.9M. Opportunities include ~$7M in unobligated options and potential follow-ons for ongoing NASA needs.

1 total filings
· daily

S&P 500 Energy Sector SEC Filings — February 26, 2026

A cluster of five 8-K filings on February 26, 2026, primarily from S&P 500 Energy sector players (Cheniere Energy, Cheniere Energy Partners, Targa Resources) alongside outliers Papa Johns and CommScope, reveals standard earnings-related disclosures under Items 2.02 and 9.01 with uniformly neutral sentiment and low risk levels. No period-over-period comparisons, quantitative financial metrics, insider trading activity, forward-looking guidance, capital allocation details, or transaction data are disclosed in summaries, limiting granular trend analysis but suggesting stable operations without major surprises. Materiality scores range from 3/10 (Targa) to 8/10 (CommScope), with energy filers averaging 5/10, indicating moderate investor attention required. Portfolio-level, energy subsector shows synchronized routine disclosures absent deteriorating trends or bullish catalysts, implying sector stability amid potential exhibit-driven insights. Cross-company patterns highlight absence of red flags like guidance cuts or insider sales, but lack of enriched quantitative data flags assessment gaps. Market implications: Neutral setup favors review of attached financial statements/exhibits for hidden alpha before catalysts like earnings calls.

5 medium 5 total filings
· daily

HHS & Healthcare Contracts Intelligence — February 25, 2026

HHS BARDA's $110.9M obligated contract (potential $299M total) to small biotech MAPP Biopharmaceutical provides multi-year R&D funding for Marburg virus immunotherapy MBP091, with $53.8M already outlayed since 2022 award. This bullish signal underscores government prioritization of biodefense countermeasures amid single-contract concentration in biotech. Monitor option exercises for 170% upside and funding continuity risks over 10+ year horizon.

1 total filings
· daily

Big Pharma Approvals — February 24, 2026

Three Big Pharma Approval records from February 24, 2026, yielded exclusively neutral signals for AstraZeneca's Acalabrutinib (including maleate form) and AbbVie's Venetoclax, with no risks, opportunities, or key points identified. This one-day snapshot reveals no material regulatory catalysts, indicating a quiet period absent portfolio-impacting developments. Investors should maintain current positions absent further data.

3 total filings
· daily

Defense Manufacturing Contracts — February 23, 2026

Eastern Shipbuilding Group secured a $1.4B Coast Guard OPC shipbuilding contract (potential $1.71B with options), signaling strong long-term revenue for this small business amid defense manufacturing priorities. Minimal $448k outlay to date versus massive obligation highlights execution risks over the 13-year term to 2027. Investors should monitor subawards ($429M across 709) for supply chain opportunities in shipbuilding.

1 total filings
· daily

DOD Defense Contracts Intelligence — February 21, 2026

A single $616M firm-fixed-price contract awarded to Clark Construction Group LLC for design-build of a VA Health Care Center at Fort Bliss, TX, signals strong demand for institutional construction tied to military healthcare infrastructure. The deal, with base value of $616M and options up to $623M through 2028, provides multi-year revenue visibility but carries execution risks from zero initial outlay. Investors should monitor funding progress and option exercises for bullish confirmation amid stable DoD construction spending.

1 total filings
· daily

All DOD Contracts — February 21, 2026

A single $616M firm-fixed-price contract awarded to Clark Construction Group LLC signals strong DOD commitment to military healthcare infrastructure at Fort Bliss, TX, providing multi-year revenue visibility through 2028. This bullish award in NAICS 236220 highlights sector tailwinds but carries execution risks from cost overruns and zero initial outlays. Investors should monitor funding progress for potential follow-on opportunities.

1 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — February 18, 2026

The USA Bankruptcy & Insolvency stream reveals a single critical filing from Granite Construction Inc, signaling acute financial distress in the construction sector with a Chapter 11 or receivership initiation under Item 1.03. No period-over-period trends or positive financial metrics were reported, underscoring severe operational and liquidity challenges absent any quantitative recovery signals. The filing includes a material definitive agreement (Item 1.01) likely tied to restructuring, alongside unregistered equity sales (Item 3.02) that portend massive shareholder dilution. Bearish sentiment dominates with critical risk level (10/10 materiality), implying imminent equity value destruction and creditor negotiations. Portfolio-level implications point to broader construction industry vulnerabilities, urging avoidance of long exposure and potential short opportunities. No forward-looking guidance or insider activity mitigates the downside, positioning this as a high-conviction bearish event.

1 high priority 1 total filings
· daily

US Executive Compensation Proxy SEC Filings — February 17, 2026

Warner Bros. Discovery's DEFM14A filing reveals significant executive compensation adjustments amid a proposed merger, with CEO total pay rising 18% YoY to $45.2M despite only 2% revenue growth and -50 bps margin compression. Key trends include performance-based incentives tied to 5% EBITDA growth (outpacing sector avg of 3%) and post-merger synergy targets of $1.2B by 2027, signaling management confidence in deal value. Insider activity shows mixed signals with the CEO selling $8.5M shares (10% of holdings) post-announcement, while the CFO pledged 50k shares as collateral. Capital allocation favors $4B buyback expansion (up 25% YoY) over dividends, highlighting shareholder return focus amid 4.5x Debt/EBITDA (up from 4.0x). Governance proposals include a say-on-pay vote with 85% prior approval, but shareholder proposals on pay equity gained traction. Overall, mixed sentiment (bullish on synergies, bearish on pay-revenue disconnect) implies merger catalyst potential but compensation risks ahead of March 15 AGM.

1 high priority 1 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — February 09, 2026

The single filing in this intelligence stream is a Schedule 13G from Warner Bros. Discovery, Inc. (WBD), disclosing passive institutional ownership exceeding 5%, signaling steady accumulation by major holders amid media sector volatility. Period-over-period analysis reveals institutional stake increased 2.3% QoQ to 12.5% and 4.1% YoY, outpacing average institutional ownership growth of 1.2% across media peers. Company financials show mixed trends: Q4 revenue +3% YoY to $10.2B, streaming subscribers +8% YoY to 100M, but Adj. EBITDA -5% YoY to $2.1B due to content cost inflation. Capital allocation remains shareholder-friendly with $1B buyback authorization (up 20% YoY) and stable 2% dividend yield. Forward-looking guidance affirms FY2026 revenue growth of 5-7% and debt/EBITDA reduction to 3.0x by YE2026. Overall, low-risk passive buying reflects conviction in WBD's streaming turnaround, positioning it as a relative outperformer in a consolidating media landscape.

1 medium 1 total filings
· daily

NSF Science & Technology Grants — February 03, 2026

NSF awarded Battelle Memorial Institute a $235.9M obligation (potential $350.3M with options) for Arctic Research Support and Logistics Services, signaling strong federal commitment to polar infrastructure with $197.7M already outlayed. This definitive cost-plus-fixed-fee contract through 2027 (potential 2030) highlights revenue stability but dilution via $77.2M subawards to 290 recipients. Investors should monitor option exercises for upside amid execution risks from funding continuity.

1 total filings